Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

5 Oct 2020

Abstract excerpt

The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYCN-amplified neuroblastoma via multiple mechanisms. CDK9 - a component of the transcription elongation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33016930
DOI: 10.1172/jci134132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaPMID 33016930Read ↗

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.Semantic proximity Read ↗

Palbociclib releases the latent differentiation capacity of neuroblastoma cellsSemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastomaSemantic proximity Read ↗

Neuroblastoma and MYCN.Semantic proximity Read ↗

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastomaSemantic proximity Read ↗

Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionSemantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationSemantic proximity Read ↗

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma CellsSemantic proximity Read ↗

Targeting MYCN in Molecularly Defined Malignant Brain TumorsSemantic proximity Read ↗

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH‐MYCN neuroblastoma mouse modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.